Aumolertinib Adjuvant Therapy of Resectable Stage I EGFRm+ NSCLC With High-grade Patterns
Clinical trial NCT04922138 · UNKNOWN
Trial details
- NCT number
- NCT04922138
- Sponsor
- Baohui Han
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-01-14
- Primary completion
- 2024-04-15
- Enrollment
- 104
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.